



## Gossamer Bio Announces Pricing of Initial Public Offering

February 7, 2019

SAN DIEGO--(BUSINESS WIRE)--Feb. 7, 2019-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its initial public offering of 17,250,000 shares of common stock at a public offering price of \$16.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on February 8, 2019 under the ticker symbol "GOSS." All of the shares are being offered by Gossamer Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Gossamer Bio, are expected to be \$276.0 million. The offering is expected to close on February 12, 2019, subject to satisfaction of customary closing conditions. In addition, Gossamer Bio has granted the underwriters a 30-day option to purchase up to an additional 2,587,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI are acting as joint book-running managers for the offering.

Registration statements relating to the shares being sold in this offering have been filed with the Securities and Exchange Commission and became effective on February 7, 2019. The offering will be made only by means of a prospectus. Copies of the prospectus may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [dg.prospectus\\_requests@baml.com](mailto:dg.prospectus_requests@baml.com); or from SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6132, or by email at [syndicate@svbleerink.com](mailto:syndicate@svbleerink.com); or from Barclays, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or by email at [barclaysprospectus@broadridge.com](mailto:barclaysprospectus@broadridge.com); or from Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at [ecm.prospectus@evercore.com](mailto:ecm.prospectus@evercore.com).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

### About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190207005935/en/>

Source: Gossamer Bio, Inc.

### Gossamer Bio:

For Investors:

Argot Partners

Kimberly Minarovich

Tel 212.600.1902

[kimberly@argotpartners.com](mailto:kimberly@argotpartners.com)

For Media:

Argot Partners

David Rosen

Tel 212.600.1902

[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)